Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.

With treatment, myasthenia gravis can generally be controlled. In fact, about 50 percent of people who have their thymus gland removed may experience long-lasting, complete remission of myasthenia ...

The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or ...

The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA(R) (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially attacking ...

Key barriers include misdiagnosis, insufficient gMG knowledge among healthcare providers, and limited access to specialists, ...

Medications for myasthenia gravis (MG) can include cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, and antibody fragment medications. While myasthenia gravis is ...

FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children Provided by GlobeNewswire Mar 10, 2025 1:09pm ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced the approval of Vyvgart for treatment of the chronic autoimmune, neuromuscular disease ...

LONDON, UK (GlobalData), 14 July 2015 - The global market for myasthenia gravis therapeutics is anticipated to more than treble in value from $146.4 million in 2014 to $550.4 million by 2024, driven ...

LONDON, Sept. 18, 2023 /PRNewswire/ -- According to a comprehensive research report by Brandessence Market Research (BMRC), "Myasthenia Gravis Treatment Market Size, Share Outlook Growth By Top ...